KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children with Intestinal Failure

Description

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

Conditions

Pediatric Intestinal Failure

Study Overview

Study Details

Study overview

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

Safety and Effectiveness of 4% Tetrasodium Ethylenediaminetetraacetic Acid Catheter Lock Solution in Preventing Central Venous Catheter Occlusions in Children with Intestinal Failure: a Randomized Controlled Trial

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children with Intestinal Failure

Condition
Pediatric Intestinal Failure
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Omaha

University of Nebraska Medical Center, Omaha, Nebraska, United States, 68198

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Fort Worth

Cook Children's Health Care System, Fort Worth, Texas, United States, 76104

Seattle

Seattle Children's Hospital, Seattle, Washington, United States, 98105

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients managed by the intestinal rehabilitation program at one of the participating centers.
  • 2. Diagnosis of intestinal failure defined as need for PN support for \>60 days in previous 74 days for primary intestinal disease (short bowel syndrome, primary motility disorder, mucosal enteropathy).
  • 3. Expectation of the treating physician that the patient will require PN for at least 6 months following enrollment.
  • 4. Age less than 18 years at diagnosis but greater than 4 weeks chronological age or 40 weeks estimated gestational age, whichever is greater.
  • 5. Stable TPN cycling (4 hours off TPN minimum per day) enabling home TPN management
  • 6. Presence of a tunneled central venous catheter (CVC), port-a-catheter, or peripherally inserted central catheter (PICC).
  • 7. Clinical stability for at least 4 weeks and no acute medical comorbidities.
  • 8. A minimum dwell time of 4 consecutive hours daily.
  • 9. Care provider willing to provide informed consent to participate in the trial and willing to comply with randomization and study protocol.
  • 1. A temporary CVC (jugular or femoral) or peripheral catheter.
  • 2. Patients receiving long-term PN, but not due to a primary intestinal disorder (i.e., oncology patients or premature neonates on PN due to intestinal immaturity).
  • 3. Known hypersensitivity, allergy, or reaction to EDTA.
  • 4. Pregnancy or nursing mother.
  • 5. Participation in another investigational device or drug trial within 30 days prior to enrollment (unless approved by the principal investigators of the trial).
  • 6. Severe coagulopathy (platelets \<50,000, or INR \> 1.5).
  • 7. Diagnosis of immunodeficiency disorder.
  • 8. Unstable medical condition requiring hospital admission
  • 9. Received antibiotic therapy for CLABSI within last 14 days.

Ages Eligible for Study

4 Weeks to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

SterileCare Inc.,

Paul Wales, MD, PRINCIPAL_INVESTIGATOR, Cincinnati Children's

Study Record Dates

2026-06